Compare Boston Scientific Corporation (BSX) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs VanEck Rare Earth/Strategic Metals — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while VanEck Rare Earth/Strategic Metals trades at $78.04. The key difference: VanEck Rare Earth/Strategic Metals is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | REMX | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Sector/Thematic |
52-Week High | $108.14 | $109.53 |
52-Week Low | $42.63 | $47.36 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $76.27, down 4.38% today amid bearish technical signals. The ETF faces high volatility (~50% annualized) and significant China concentration risk, though recent news highlights growing institutional interest in rare earths as critical for AI and defense infrastructure. Technical indicators show oversold RSI readings but dominant bearish moving average signals.
Outlook remains speculative given geopolitical supply chain dependencies and commodity price sensitivity. Investment appeal hinges on long-term rare earth demand growth from technology and energy transitions, but risks include China export controls and ETF liquidity constraints. Current levels near support at $76 may attract tactical buyers despite near-term bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
